Quarterly report pursuant to Section 13 or 15(d)

Revenue Information

v3.10.0.1
Revenue Information
9 Months Ended
Sep. 30, 2018
Segment Reporting [Abstract]  
Revenue Information

Note 11 – Revenue Information

 

Revenue by product lines was as follows:

 

    Three months ended     Nine months ended  
    September 30,     September 30,  
Product Line   2018     2017     2018     2017  
                         
MicroParticle Catalyzed Biosensor (“MPC”)   $ (18,798 )   $ 104,094     $ 106,832     $ 259,601  
Particle ImmunoFiltration Assay (“PIFA”)     567,262       490,058       1,183,327       1,477,726  
Rapid Enzymatic Assay (“REA”)     -       27,500       55,000       27,500  
Other     8,625       16,679       41,006       613,614  
Product Revenue Total     557,089       638,331       1,386,165       2,378,441  
License Fees     -       37,500       -       37,500  
Total Revenue   $ 557,089     $ 675,831     $ 1,386,165     $ 2,415,941  

 

The total revenue by geographic area determined based on the location of the customers was as follows:

 

    Three Months Ended     Nine Months Ended  
    September 30,     September 30,  
Geographic Region   2018     2017     2018     2017  
United States   $ 554,269     $ 626,077     $ 1,311,360     $ 1,755,558  
People’s Republic of China     -       -       -       502,268  
Rest of World     2,820       49,754       74,805       158,115  
Total Revenue   $ 557,089     $ 675,831     $ 1,386,165     $ 2,415,941  

 

The Company had long-lived assets totaling $59,355 and $59,830 located in the People’s Republic of China and $1,201,592 and $1,305,950 located in the United States as of September 30, 2018 and December 31, 2017, respectively.